Table 1 Demographic and clinical characteristics of the patient and each group at baseline and time length of each period.

From: The impact of time length to Boolean remission for tight disease activity control after acquisition in rheumatoid arthritis patients

 

In all

G ≤ 6

G > 6

p-value

Cases

465

323

142

 

Female (%)

343 (73.7%)

245 (76.8%)

98 (69.0%)

0.12

Age

67.8 (13.9), 69, 21–95

67.6 (14.1), 69, 25–95

68.2, 13.4, 69, 21–93

0.81

Disease duration

6.1 (7.9), 3.75, 0.1–45

5.4, 7.5, 3, 0.1–45

7.7 (8.6), 5, 0.1–45

< 0.001

ACPA positive (%)

336 (72.3%)

232 (71.8%)

104 (73.2%)

0.75

RF positive (%)

350 (75.3%)

243 (75.2%)

107 (75.4%)

0.98

MTX use

254 (54.6%)

180 (55.7%)

74 (52.1%)

0.54

b/tsDMARD use

44 (9.5%)

23 (7.1%)

21 (14.8%)

0.18

GCS use

128 (27.5%)

81 (25.1%)

47 (33.1%)

0.21

TJC

2.3 (3.0), 1, 0–20

2.2 (3.1), 1, 0–20

2.5 (2.9), 2, 0–19

< 0.05

SJC

3.9 (4.8), 2, 0–28

4.0 (5.2), 2, 0–28

3.8 (4.8), 3, 0–16

0.24

PGA

2.9 (2.8), 2, 0–10

2.8 (2.9), 2, 0–10

3.3 (2.7), 3, 0–10

< 0.05

EGA

2.2 (2.1), 2, 0–10

2.1 (2.1), 2, 0–10

2.3 (1.9), 2, 0–10

0.16

CRP

14.0 (27.0), 2.7, 0–207.0

15.0 (29.0), 2.8, 0–207.0

14.0 (22.0), 2.7, 0–144.0

0.25

DAS28

3.9 (1.2), 2.5, 2.6–6.4

3.8 (1.2), 2.4, 2.6–6.4

3.9 (1.0), 2.6, 2.6–5.5

0.13

CDAI

11.8 (10.5), 8.5, 4–66

11.8 (11.3), 7.5, 7–66

11.9 (8.6), 10.8, 4–56

0.45

SDAI

13.3 (12.2), 8.8, 4.3–71.1

13.3 (12.9), 7.7, 7.4–71.1

13.3 (9.8), 11.3, 4.3–64.4

0.68

HAQ-DI

0.467 (0.582), 0.250, 0–2.75

0.418 (0.564), 0.125, 0–2.75

0.578 (0.607), 0.375, 0–2.625

< 0.01

PS-VAS

33.2 (29.5), 25, 0–100

30.3 (28.9), 20, 0–100

40.5 (29.6), 47.5, 0–100

< 0.001

SHS

47.9 (62.9), 22, 0–340

28.3 (51.3), 19, 0–296

69.1 (78.9), 35, 0–340

< 0.001

QOLS

0.83 (0.12), 0.89, 0.19–0.94

0.85 (0.13), 0.89, 0.19–0.94

0.81 (0.11), 0.82, 0.59–0.94

< 0.001

Total follow-up length (months)

71.5 (33.3), 55, 36–122

70.7 (33.9), 63, 36–122

73.3 (31.9), 45.5, 36–122

0.18

From baseline to first Boolean remission (months)

8.1 (13.2), 4, 1–111

2.7 (1.6), 2, 1–6

18.7 (8.1), 14, 7–111

< 0.001

From first Boolean remission to last observation (months)

79.4 (38.6), 55, 4–121

84.6 (42.3), 63, 30–121

71.3 (35.8), 46, 4–115

< 0.001

Total consult times

48.7 (38.7), 40, 10–185

46.2 (37.8), 39, 10–180

54.5 (40.2), 45, 10–185

< 0.05

  1. G ≤ 6, a patient group who achieved Boolean remission within 6 months from the baseline; G > 6, a patient group who achieved Boolean remission longer than 6 months from the baseline; ACPA anti-cyclic citrullinated polypeptide antibodies, RF rheumatoid factor, MTX methotrexate, b/tsDMARD biologic/targeted disease-modifying anti-rheumatic drug, GCS glucocorticoid steroid, TJC tenderness joint count, SJC swollen joint count, PGA patient's global assessment, EGA evaluator's global assessment, CRP C-reactive protein, DAS28 28-joints disease activity score, CDAI clinical disease activity index, SDAI simplified disease activity index, HAQ-DI Health Assessment Questionnaire Disability Index, PS-VAS pain score using visual analog scale, SHS Sharp/van der Heijde Score, QOLS quality of life score.
  2. Units: age, year old; disease duration, years; CRP, mg/L; PS-VAS, millimeter. The other parameters' units are numerical values.
  3. Except Female, ACPA positive, and RF positive, mean value (standard deviation), median, and range separated with comma are shown. In Female, ACPA positive, and RF positive, real numbers and their ratios in the parentheses are shown.
  4. In Female, ACPA positive, and RF positive, p-values were calculated using chi square test, while in the other parameters, Mann–Whitney U-test for the statistical comparison between the G ≤ 6 and the G > 6 was used.
  5. Statistically significant columns are shown in bold style.
Back to article page